Daly James M
SEC Form 4 insider trading activity
Daly James M has filed 7 SEC Form 4 filings (7 transaction rows) across 3 companies, including CYTK, MDGL, ACAD, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Jul 16, 2026.
On the most recent filing, Daly James M is listed as Director at ACADIA PHARMACEUTICALS INC. Inside the rolling window, Daly James M reported no open-market purchases and 1 open-market sale totaling $671K in ACAD.
Companies traded
Other insiders at CYTK
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$671K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Daly James M made?
Daly James M has filed 7 SEC Form 4 filings (7 transaction rows) across 3 companies, including CYTK, MDGL, ACAD since 2025.
Which companies does Daly James M trade?
Daly James M has filed SEC Form 4 disclosures for 3 companies, including CYTK, MDGL, ACAD.
When was Daly James M's most recent SEC Form 4 filing?
Daly James M's most recent SEC Form 4 filing on Tracefour is dated Jul 16, 2026.
What is Daly James M's total buy and sell value in the current window?
Inside the rolling retention window, Daly James M bought $0 and sold $671K based on SEC Form 4 filings.
What was Daly James M's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 30,000 ACAD shares on 2025-11-10, worth $671K, per SEC Form 4 filings.